We have selected a well-characterized human renal cell carcinoma (RCC) line as the basis for development of a genetically engineered tumor cell vaccine to be applied in an allogeneic setting. This cell line was genetically modified by retroviral transduction to express B7.1 costimulatory molecules. The unmodified tumor cells and B7.1-expressing tumor cells were compared for their ability to induce tumorassociated responses in allogeneic peripheral blood mononuclear cells (PBMC) of two normal control donors having single MHC class I allele matches with the tumor cells. PBMC primed using B7.1-modified tumor cells showed a preponderance of CD3 +
Introduction
Because of the technical difficulties and high costs of preparing patient-specific autologous tumor cell vaccines ex vivo, much consideration is being given to using genetically modified allogeneic tumor cell vaccines. 1 Allogeneic vaccine strategies have the advantage that well-characterized, immunogenic tumor cell lines can be selected for use that are available in unlimited numbers and their genetic engineering, selection and characterization need only be performed once. It has been speculated that strong allogeneic responses by patient lymphocytes directed against mismatched MHC molecules of the vaccine cells may be so dominant that weaker, tumor-associated responses will not develop. Animal tumor models suggest, however, that allogeneic responses may actually enhance the development of tumor protection against syngeneic tumors in vivo. [2] [3] [4] [5] [6] Furthermore, it was shown that an allogeneic response supported the generation of tumor-antigen specific T cells that were capable of eliminating established metastases in a murine model. 6, 7 In order to assess the feasibility of using an allogeneic strategy for vaccination of patients with metastatic RCC, that proliferated over extended periods of time in mixed lymphocyte tumor cell (MLTC) cultures. Strong cytolytic activity developed in the primed populations and included allospecific CTL with specificity for mismatched HLA-A, -B and -C molecules. Nevertheless, it was possible to isolate CTL clones that were able to lyse tumor cells but not lymphoblastoid cells that expressed all the corresponding allospecificities. Thus, induction of complex allospecific responses did not hinder the development of tumor-associated CTL in vitro. These results support the use of this genetically modified allogeneic tumor cell line for vaccination of partial-MHC matched RCC patients. Gene Therapy (2000) 7, 2007-2014.
we selected a locally derived RCC line based on its immunogenic potential. The RCC-26 tumor line was established from the primary tumor of a patient with stage I disease. The tumor-infiltrating lymphocytes (TIL) present in the primary tumor contained a population of CTL that lysed autologous tumor cells, but not autologous normal kidney cells or the MHC class I negative target cells, Daudi and K562. 8 One tumor-antigen specific ligand of RCC-26 recognized by autologous CTL was found to be restricted by the MHC class I molecule encoded by the common HLA-A * 0201 allele. The T cell receptors (TCR) utilized by these CTL were found to have characteristic sequences and to be highly prevalent in vivo. 9 Furthermore, several TIL isolated from other HLA-A * 0201 patients were able to lyse RCC-26 cells in vitro through recognition of several apparently distinct determinants. 8, 10 Therefore, the RCC-26 tumor line expresses several tumor-associated ligands that are shared by tumors of other RCC patients and HLA-A * 0201-restricted CTL specific for these ligands were induced in vivo in different RCC patients. These functional studies indicated that RCC-26 cells could be used in an allogeneic setting to reactivate memory CTL in such patients.
Here we describe functional studies analyzing the specificity of CTL responses that were induced in vitro against tumor cells in the PBMC of allogeneic donors who had single class I matches with the RCC-26 cells. Responding lymphocytes were activated by multiple rounds of stimulation in MLTC using unmodified RCC-26 cells or RCC-26 cells that were genetically engineered to express the costimulatory molecule B7.1 (RCC-26/B7.1). Earlier studies in animals revealed that tumor cells modified to express B7.1 costimulatory molecules had enhanced immunogenicity and were capable of inducing immune responses in naive animals that could protect against challenge with unmodified tumor cells. [11] [12] [13] [14] [15] [16] [17] Introduction of B7.1 into several human tumor lines also improved their immunogenicity in vitro and in some cases led to activation of specific CTL.
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Results
Surface expression of MHC class I, class II and B7.1 molecules on RCC-26 cells Tumor cells of RCC-patient 26 were isolated from the primary tumor and a long term cell line (RCC-26) was established in vitro as described previously. 8 The EBV-transformed lymphoblastoid cell line (LCL-26) was generated from autologous peripheral blood mononuclear cells (PBMC). After maintenance for more than 30 passages in vitro the RCC-26 tumor cell line was transduced with a retroviral vector encoding the B7.1 (CD80) costimulatory molecule. A sequence encoding a hygromycin-thymidine kinase (HyTK) fusion protein was cointroduced in the same vector. The uncloned population of RCC-26/B7.1 cells was maintained over months in hygromycin-containing selection medium. Expression of B7.1 molecules by this population was compared with that of unmodified RCC-26 cells, a vector control line of RCC-26 cells transduced to express the HyTK fusion protein in the absence of B7.1 (RCC-26/HyTK) and autologous LCL-26 cells. The expression of MHC class I and class II molecules was analyzed in parallel. As illustrated in Figure  1 , all four cell lines expressed substantial levels of MHC class I molecules, whereas only LCL-26 cells bound the monoclonal antibody specific for MHC class II molecules. Neither unmodified RCC-26 cells nor the vector control line bound the B7.1-specific reagent at levels above those After three rounds of restimulation the phenotypes of the responding lymphocytes were determined by immunofluorescence staining using various mab ( 
Generation of activated lymphocytes in MLTC
CD8
+ populations in all four MLTC (data not shown).
Cytotoxic activity and specificity of allogeneic MLTC Cytotoxic activity of the MLTC primed lymphocytes was analyzed after three rounds of restimulation with tumor cells using a standard 4 h chromium-release assay. Substantial levels of cytolytic activity were detected in all four MLTC and they were comparably strong in MLTC primed using either unmodified or modified tumor cells for stimulation ( Figure 3) . Thus, the expression of B7.1 by the tumor cells seemed to influence the expansion of the CD3 +
+ CTL but not their degree of cytolytic activity. The specificity of all four MLTC appeared to be quite similar since both unmodified and RCC-26/B7.1 tumor cells were lysed to a substantial degree while the class I negative target cells, Daudi and K562, were recognized to only a minimal degree. While it appeared that the unmodified RCC-26 cells induced higher levels of CTL activity in the DS cultures, this was not seen with the cultures of donor JB or other unrelated donors (data not shown), so that this most likely reflects technical variation in the in vitro cultures. Enhanced triggering of effector cells via B7.1 molecules did not appear to contribute Gene Therapy to the level of specific lysis since the B7.1-expressing target cells were not better targets for these T cell populations.
The high levels of cytotoxicity directed against the RCC-26 cells, combined with the observation from additional experiments that LCL-26 cells were also lysed to a substantial degree (data not shown), suggested that strong allospecific CTL responses were induced in these MLTC. To demonstrate that this was the case and to assess the fine specificity of these responses, a panel of allogeneic LCL was tested for susceptibility to lysis. These LCL were selected to be matched for single MHC alleles with RCC-26 cells, so that each allogeneic determinant expressed by RCC-26 cells could be evaluated individually by the testing of one LCL. An example of this analysis is shown for the MLTC using PBMC of donor DS ( Figure 4 ). CTL activity directed against molecules encoded by the A * 3303 allele, both B alleles and both C alleles was detected in cultures primed to either unmodified RCC-26 cells or those engineered to express B7.1. As presumed for a classical alloresponse, CTL specific for A * 0201 were not generated since donor DS, like RCC-26, carries an HLA-A * 0201 allele. At the level of individual allospecificities, it appeared that there was somewhat better recognition by the CTL primed with RCC-26/B7.1 tumor cells. CTL specific for most mismatched alloantigens were also found in JB anti-RCC-26 and JB anti-RCC-26/B7.1 cultures (data not shown). These experiments revealed that complex allogeneic responses were primed in vitro using RCC-26/B7.1 tumor cells. Substantial differences in overall levels of alloreactivity and in fine specificity were not apparent when B7.1-expressing tumor cells were compared with unmodified RCC-26 cells (data not shown).
RCC-26-associated CTL are generated in allogeneic MLTC To search for the presence of RCC-26-associated CTL in the allogeneic MLTC, short-term cultures were derived by limiting dilution using the remaining PBMC that were primed against the B7.1-expressing tumor cells that had retained proliferative capacity after four rounds of restimulation. Insufficient proliferation of the T cells primed against unmodified tumor cells precluded their further analysis (see Figure 2 ). Cultures were plated at five, one and 0.5 cells per well and selected colonies that showed adequate growth in the original 96-well plates after 20-25 days were tested for cytolytic activity directed against unmodified RCC-26 and LCL-26 target cells. Each selected well was split into three aliquots, two of which were used for analysis of cytotoxic specificity, whereas the third was used for molecular TCR characterization. In cytotoxicity assays, lysis of LCL-26 cells, served to identify allospecific responses since LCL-26 express the MHC alloantigens of RCC-26 cells but do not express tumor-associated or tissue-associated ligands displayed by RCC-26 cells to which the PBMC were exposed during the priming phase. Alternatively, CTL showing lysis of RCC-26 cells, but not recognizing LCL-26 cells, lack specificity for MHC alloantigens since these are expressed by both targets. Therefore, these CTL recognize non-allogeneic, RCC-26-associated ligands.
From both MLTC, cytotoxic cultures derived from cells plated at five cells per well were predominantly allospecific, with recognition of LCL-26 cells ranging from 11 to 69% lysis (data not shown). These cytotoxic cultures also lysed RCC-26 cells, albeit at somewhat lower levels (4-50%), indicating that the MHC alloantigens were better expressed on the LCL-26 cells. From the DS-MLTC, the 12 cultures seeded at one or 0.5 cells per well that showed adequate proliferation microscopically were all found to have cytotoxic activity with the CTL showing more than 10% lysis of one target cell ( Figure 5 ). Only two cultures appeared to be allospecific, lysing the LCL-26 target cells with a percentage of specific lysis of more than 10%. The allodeterminants seen by these two cultures were poorly expressed by the RCC-26 cells (Ͻ10% specific lysis). For the other 10 cultures, lysis was directed predominantly against RCC-26 cells and lysis of LCL-26 was marginal, demonstrating their specificity for RCC-26-associated epitopes. Six cultures of the 12 selected by microscopic growth from the JB-MLTC showed more than 10% lysis of one target cell. Three appeared to be allospecific, recognizing both LCL-26 and RCC-26 cells; whereas the other three only recognized tumor cells, indicating a specificity for RCC-26-associated ligands. These results indicated that CTL able to recognize non-allogeneic ligands on the RCC-26 tumor cells developed in these MLTC despite the induction of broad allogeneic responses.
Quantitation of V␣20 TCR-positive T cells in B7.1-primed allogeneic cultures Parallel analyses of TCR usage revealed that two clones from the DS-MLTC that showed preferential lysis of RCC-26 cells utilized V␣20 alpha chains ( Figure 5 ). Sequencing of their CDR3 regions showed that both alpha chains were identical (data not shown), demonstrating that these two cultures were clonal derivates of one T cell that had expanded in the priming culture. Interestingly, the CDR3 region of these alpha chains was highly homologous to the CDR3 regions of a family of TCR that were found to predominate in situ in the tumors of two RCC patients who also carried HLA-A * 0201 alleles; in fact, the CDR3 amino acid sequence of these alpha chains was identical to a sequence found in the tumor of one of these patients. 9 We used the V␣20 sequence as a molecular marker to estimate the number of V␣20 positive T cells bearing this receptor present in the MLTC following three rounds of restimulation using the LightCycler system. This newly available real-time PCR method overcomes many of the difficulties of conventional semiquantitative RT-PCR methods. Identifying the first cycle of the PCR run in which the log-linear signal can be distinguished from the background allowed rapid and reliable quantification of target TCR gene expression ( Figure 6 ). Serially diluted cloned V␣20 positive CTL isolated from the TIL of patient 26 were used to generate standard curves. Samples containing 1000 to 10 000 V␣20 positive T cells were admixed with cells of a V␣20 negative T cell clone to give a final cell number of 0.5 × 10 6 cells. RNA was isolated from the individually mixed samples, reverse transcribed into cDNA and analyzed by real-time PCR. The x-axis crossing point of each standard dilution was measured and plotted against the logarithm of the V␣20 cell concentration to generate a highly reproducible standard curve (data not shown). The experimental curve was generated using 0.5 × 10 6 cells of the allogeneic MLTC using donor DS lymphocytes primed with the RCC-26/B7.1 cell line, after three rounds of restimulation. The calculated number of V␣20 positive cells extrapolated from the standard curve was 1350 cells per 0.5 × 10 6 total cells, giving a 
Discussion
Renal cell carcinomas have been classified as immunogeneic tumors in man based on spontaneous tumor remission in a small number of patients and on clinical responsiveness to systemic cytokine therapy. 26 MHCrestricted CTL recognizing RCC have been isolated, but little is known about the determinants that are recognized so that peptide or DNA-based vaccines lag in development. An alternative strategy to induce or reactivate pre-existing immune responses in patients with metastatic RCC is to use tumor cell-based vaccines that have been genetically engineered to express molecules that enhance their immunostimulatory capacities. Allogeneic vaccines offer a practical source of vaccine cells if tumor lines can be identified that express MHCrestricted epitopes that are common to tumors of partially MHC-matched patients.
The experiments described in this paper were designed to determine whether the renal cell carcinoma line, RCC-26, which was genetically engineered to express B7.1 costimulatory molecules is suitable for use as an allogeneic tumor cell vaccine. This particular RCC line was selected because it was well-characterized with respect to its MHC class I molecules and a corresponding autologous LCL was available that allowed RCC-26-associated and allospecific responses to be distinguished at a functional level. The results demonstrate that this tumor line displays characteristics that support its use in the development of an allogeneic vaccine for RCC patients. RCC-26 cells showed a surprising priming capacity in the allogeneic MLTC. This was reflected in the high levels of cellular proliferation, strong cytotoxic potential and fine specificity of the CTL responses generated from the PBMC of two unrelated donors. The genetic modification The nature of the RCC-26-associated ligands seen by such CTL remains to be determined. These CTL may, for example, recognize ligands derived from proteins that are uniquely expressed in the tumor cells (ie tumor antigen-specific) or they may recognize ligands derived from proteins that are expressed in epithelial cells but not in hematopoietic cells (ie tissue-associated ligands). The two V␣20 clones had CDR3 sequences that were homologous to sequences present in a family of TCR that were highly prevalent in situ in the primary tumors of two HLA-A * 0201 RCC patients. 9 Such V␣20 positive CTL dominated the TIL population of patient 26 from whom the RCC-26 line was derived. These CTL were shown to recognize an apparently immunodominant, tumor antigen-specific epitope presented by HLA-A2 molecules on RCC-26 cells, since this epitope was not recognized by the CTL on normal kidney cells of patient 26. 8 It is intriguing to find that similar T cells emerged from the peripheral repertoire of a healthy HLA-A * 0201 donor following stimulation with RCC-26/B7.1 cells in the allogeneic MLTC, indicating that this epitope could also drive naive T cells with this specificity to proliferate in vitro.
Studies of TIL isolated from HLA-A * 0201 patients suggest that RCC-26 cells present several different tumorassociated ligands via HLA-A2 molecules. 8, 10 The colonies derived from the JB-MLTC reveal that other potential tumor-associated peptides were presented by MHC molecules other than HLA-A2 since this donor does not have an HLA-A * 0201 allele. The B * 5101 allele is shared by donor JB and patient 26 and may function to present RCC-26-associated peptides to these CTL. The role of HLA-C molecules in peptide presentation also needs to be evaluated in more detail since they have been shown to effectively present melanoma-associated peptides. 27, 28 The identification of additional MHC restriction elements presenting a variety of tumor-associated peptides opens the possibility to utilize an RCC-26 based vaccine to reactivate memory CTL in patients having other matched HLA alleles.
These experiments do not allow us to determine whether the RCC-26-associated responses were primed directly by the tumor cells or were induced through indirect priming, since autologous antigen presenting cells were not deleted from the responding PBMC. It does, however, appear that RCC-26 cells directly primed the allospecific CTL. The generation of these allospecific CTL through an indirect priming mechanism would require that autologous antigen presenting cells of both donors processed and presented peptides derived from multiple mismatched HLA alloantigens in a way that precisely reflected the alloantigenic specificities displayed by the LCL target cell panel used for fine specificity analysis. Therefore, it seems more likely that RCC-26 cells directly stimulated these allospecific CTL in vitro.
Other groups have previously analyzed B7.1 or B7.2-modified tumor cells for their capacity to induce CTL responses. [29] [30] [31] [32] [33] [34] [35] [36] In the case of melanoma lines, B7 expression appeared to be necessary to induce allogeneic responses; whereas this was not found to be the case here with the RCC-26 renal carcinoma line. Although it has been found that CTL responses directed against tumorassociated antigens could be induced following stimulation with B7-modified melanoma lines, the priming procedures utilized purified CD8 T cells and culture conditions that did not support the development of alloresponses; 32, 33 thus, the influence of dominating allospecific CTL on development of tumor-specific CTL could not be assessed in these studies. While such priming strategies are useful for generating tumor-specific CTL in vitro for use in adoptive transfer they do not reflect the situation that will occur if allogeneic tumor cells are applied as vaccines in vivo. Here the exposure of PBMC, containing CD4, CD8 and antigen-presenting cells, to allogeneic tumor cells is expected to induce strong allogeneic responses. Meyer et al 36 were able to demonstrate that allogeneic breast carcinoma cells genetically modified to express B7.1 and an influenza-derived protein were able to prime flu peptide-specific CTL alongside induction of strong alloresponses. Since the surrogate influenza antigen in this system represented a transgenic foreign protein that is highly visible to the immune system, it may be that the alloresponsive CTL did not over-dominate the response, allowing flu-specific CTL to arise. Our results extend these observations by demonstrating that even naturally expressed ligands of tumor cells can induce CTL in parallel with the development of dominating alloreactivity. In conclusion, the potential of RCC-26 cells to directly prime T cells, to reactivate memory CTL that develop in RCC patients in vivo and to serve as a reservoir of tumor-associated proteins for indirect priming supports the use of genetically engineered RCC-26 cells for vaccination in an allogeneic setting.
Materials and methods
Establishment of cell lines and cytotoxic effector cells
The renal cell carcinoma line, RCC-26, was established locally as described 8 and cultured in RPMI 1640 medium supplemented with 2 mm l-glutamine, 1 mm sodiumpyruvate, 1 × non-essential amino acids and 10% heatinactivated fetal calf serum (FCS). Epstein-Barr virus (EBV)-transformed lymphoblastoid cell lines (LCL) were generated from patient 26 and other healthy control donors using culture supernatants of the marmoset cell line producing the B95.8 strain of EBV obtained from the American Type Culture Collection (ATCC, Rockville, MD, USA). HLA serotyping and molecular sequencing revealed the following alleles in patient 26: HLA-A * 0201, A * 3303, B41, B * 5101, Cw * 1502 and Cw * 1701.
MLTC were established using PBMC of healthy, HLAtyped control donors and irradiated (100 Gy) tumor cells, plating 0.5 × 10 6 responding cells and 3 × 10 4 irradiated tumor cells per well of a 24-well culture plate, in medium consisting of RPMI 1640 supplemented with 2 mm l-glutamine, 1 mm sodium-pyruvate and 10% heat-inactivated pooled human serum. 37 Four days after initiation of the cultures, 20 units/ml recombinant interleukin-2 (rIL-2; Proleukin), kindly provided by Chiron Corporation (Ratingen, Germany), and 5 units/ml recombinant rIL-4 38 were added to all cultures. Responding lymphocytes were restimulated at intervals of 8-10 days using irradiated (100 Gy) tumor cells, in medium supplemented with exogenous rIL-2 and rIL-4. Short-term limiting dilution cultures were derived by plating five, one or 0. 
Generation of RCC transductants
The retroviral vector HyTK-CMV-hB7.1 has been described previously. 39 It contains a hygromycin-thymidine kinase fusion gene as a selectable marker under the control of the Moloney murine leukemia virus long terminal repeat and the cDNA of human B7.1 driven by the internal cytomegalovirus promoter. Retroviral infection and selection in hygromycin B (0.6 mg/ml) supplied by Calbiochem (La Jolla, CA, USA) was done as described and resulted in the generation of the RCC-26/B7.1 line.
Cell-mediated cytotoxicity assay Cell-mediated lysis was quantitated in a standard 4 h chromium-51 release assay. 40 Spontaneous release was determined by incubating target cells alone in complete medium. Total release was determined by directly counting an aliquot of labeled cells. The percent cytotoxicity was calculated according to the formula: % lysis = (experimental c.p.m. -spontaneous c.p.m./total c.p.m. -spontaneous c.p.m.) × 100. Duplicate measurements of three step titrations of effector cells were used for all experiments, except for the limiting dilution cultures which were only tested at one concentration.
Indirect immunofluorescence Tumor cells were tested for surface expression of MHC class I, class II and B7.1 (CD80) molecules by flow cyto-metry using the following monoclonal antibodies (mab): W6/32 specific for MHC class I molecules (ATCC); L243 specific for HLA-DR (ATCC), and B7.1-specific mab supplied by Immunotech (Hamburg, Germany). Mabs UPC-10 and MOPC-21 purchased from Sigma Chemical (Deisenhofen, Germany) and specific for mouse myeloma proteins served as isotype controls. Cells were incubated with mab for 90 min on ice, washed twice with PBS and then incubated 30 min with fluorescein-isothiocyanate (FITC)-conjugated rabbit-anti-mouse F(ab) 2 (F313) supplied by Dakopatts (Copenhagen, Denmark). Cells were analyzed using a FACScan flow cytometer (Becton Dickinson, Mountain View, CA, USA).
Effector cells were characterized for their lymphocyte composition with mab specific for defined surface molecules. Directly labeled FITC or phycoerythrin-(PE) mab binding to CD3 (clone UCHT1), CD4 (clone 13B8.2), CD8 (clone B159) were supplied by Immunotech and CD56 (clone NKH-1) purchased from Coulter (Hialeah, FL, USA). After 30 min incubation at 4°C and washing, staining was evaluated by flow cytometry. In brief, 5 × 10 5 cells were harvested, washed in culture medium and lysed in 200 l of TriReagent (Biozol, Eching, Germany). After isolation of total cellular RNA according to the manufacturer's instructions, RNA was adjusted to 0.6 g/l and an aliquot of 8 l was reverse transcribed with a TCR alpha-chain specific oligonucleotide (C␣ST(RT): 5Ј CAC TGA AGA TCC ATC ATC TG 3Ј) using the Superscript II reverse transcriptase (GibcoBRL, Germany), as described previously. 9 PCR amplification was performed with the LightCycler FastStart Reaction Mix SYBR Green I (Roche) which is a ready-to-use 'Hot Start' reaction mix for PCR, using a V-alpha family specific primer (TCRAV20 forward primer: 5Ј CAT CTC CAT GGA CTC ATA TGA 3Ј) combined with an alpha constant region primer (T-C␣ reverse primer: 5Ј GGT GAA TAG GCA GAC AGA CTT GTC ACT GGA 3Ј).
For each LightCycler reaction, a master mix of 18 l was prepared, containing 4 mm MgCl 2 , 7.5 pmol forward primer, 15 pmol reverse primer and 2 l of the LightCycler FastStart DNA Master SYBR Green I. A total of 18 l master mix and 2 l of cDNA was added to each glass capillary placed in adapters. Sealed capillaries were centrifuged briefly with the adapters in a microcentrifuge and placed in the LightCycler rotor. The following LightCycler protocol was used for online detection of amplified products using SYBR Green I, including a three-segment PCR amplification and melting curve program: initial denaturation at 95°C for 10 min, a 40 cycles amplification for 1 s at 95°C, 10 s at 58°C, and 25 s at 72°C.
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Melting curve analysis and cooling was done according to the manufacturer's instructions.
